Tokyo, Jan. 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060484) titled 'Comparative efficacy and safety of vonoprazan- and rabeprazole-based triple therapy in second-line Helicobacter pylori eradication' on Jan. 27.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Active
Primary Sponsor:
Institute - Fuyoukai Murakami Hospital
Condition:
Condition - H. pylori infection
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Efficacy and safety of second-line H. pylori eradication
Basic objectives2 - Safety,Efficacy
Intervention:
Interventions/Control_1 - Vonoprazan-based triple therapy in second-line H. pylori eradication
Interventions/Control_2 - Rabeprazole-based triple therapy in second-line H. pylori eradication
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who received VPZ-based or RPZ-based triple therapy for second-line H. pylori eradication in Fuyoukai Murakami Hospital from 1 March 2015 to 28 February 2022
Key exclusion criteria - None
Target Size - 92
Recruitment Status:
Recruitment status - Completed
Date of protocol fixation - 2015 Year 03 Month 01 Day
Date of IRB - 2025 Year 12 Month 01 Day
Anticipated trial start date - 2015 Year 03 Month 01 Day
Last follow-up date - 2025 Year 11 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069194
Disclaimer: Curated by HT Syndication.
